MA38425A1 - Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 - Google Patents

Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1

Info

Publication number
MA38425A1
MA38425A1 MA38425A MA38425A MA38425A1 MA 38425 A1 MA38425 A1 MA 38425A1 MA 38425 A MA38425 A MA 38425A MA 38425 A MA38425 A MA 38425A MA 38425 A1 MA38425 A1 MA 38425A1
Authority
MA
Morocco
Prior art keywords
compounds
selective agonists
receptor
bicyclic compounds
diseases
Prior art date
Application number
MA38425A
Other languages
English (en)
Other versions
MA38425B1 (fr
Inventor
Marta Dabros
T G Murali Dhar
Hai Yun Xiao
Alaric J Dyckman
Eric J Chan
Daniel Richard Roberts
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA38425A1 publication Critical patent/MA38425A1/fr
Publication of MA38425B1 publication Critical patent/MA38425B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (i) et/ou un de leurs sels; dans laquelle r représente -oh ou -op(o)(oh)2. L'invention concerne également des méthodes d'utilisation de tels composés comme agonistes sélectifs pour le récepteur s1p1couplé à la protéine g, et des compositions pharmaceutiques comprenant de tels composés. Ces composés sont utiles dans le traitement, la prévention, ou le ralentissement de la progression de maladies ou de troubles dans des domaines thérapeutiques variés, tels que ceux des maladies auto-immunes et des maladies vasculaires.
MA38425A 2013-02-21 2014-02-21 Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 MA38425B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (fr) 2013-02-21 2014-02-21 Composés bicycliques

Publications (2)

Publication Number Publication Date
MA38425A1 true MA38425A1 (fr) 2017-12-29
MA38425B1 MA38425B1 (fr) 2019-03-29

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38425A MA38425B1 (fr) 2013-02-21 2014-02-21 Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1

Country Status (34)

Country Link
US (3) US9115054B2 (fr)
EP (1) EP2958888B1 (fr)
JP (1) JP6277210B2 (fr)
KR (1) KR102242265B1 (fr)
CN (1) CN105026362B (fr)
AR (1) AR094851A1 (fr)
AU (1) AU2014218883B2 (fr)
BR (1) BR112015019919A2 (fr)
CA (1) CA2902168C (fr)
CL (1) CL2015002358A1 (fr)
CY (1) CY1118641T1 (fr)
DK (1) DK2958888T3 (fr)
EA (1) EA025294B1 (fr)
ES (1) ES2613262T3 (fr)
HR (1) HRP20170247T1 (fr)
HU (1) HUE031626T2 (fr)
IL (1) IL240613B (fr)
LT (1) LT2958888T (fr)
MA (1) MA38425B1 (fr)
MX (1) MX2015010347A (fr)
MY (1) MY173990A (fr)
PE (1) PE20151746A1 (fr)
PH (1) PH12015501793B1 (fr)
PL (1) PL2958888T3 (fr)
PT (1) PT2958888T (fr)
RS (1) RS55703B1 (fr)
SG (1) SG11201506408TA (fr)
SI (1) SI2958888T1 (fr)
SM (2) SMT201700115T1 (fr)
TN (1) TN2015000356A1 (fr)
TW (1) TWI613182B (fr)
UY (1) UY35338A (fr)
WO (1) WO2014130752A2 (fr)
ZA (1) ZA201506965B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009731A2 (fr) 2013-07-15 2015-01-22 The Regents Of The University Of California Analogues azacycliques de fty720 à structure contrainte
UY36274A (es) * 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
EP3352753A4 (fr) * 2015-09-24 2019-03-13 The Regents of The University of California Molécules de type sphingolipide synthétiques, médicaments, procédés pour leur synthèse et procédés de traitement
KR102482825B1 (ko) 2016-09-02 2022-12-29 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2021062168A1 (fr) * 2019-09-25 2021-04-01 The Regents Of The University Of California Molécules inspirees par des sphingolipides synthetiques ayant des groupes pendants heteroaromatiques cytotoxiques, leurs procédés de synthèse et méthodes de traitement
WO2025083549A1 (fr) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Méthodes et combinaisons d'inhibiteurs de la voie il-23 et de modulateurs de la voie de signalisation s1p pour le traitement de maladies auto-immunes

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
EP1469863A2 (fr) 2002-01-18 2004-10-27 Merck & Co., Inc. Antagonisteses lectifs du recepteur s1p1/edg1
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
EP1549640A4 (fr) 2002-06-17 2008-08-06 Merck & Co Inc 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg
EP1628967B1 (fr) 2003-05-19 2014-04-09 Irm Llc Composés immunosuppresseurs et compositions
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CA2583681A1 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
CA2596990A1 (fr) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Agonistes de sphingosine-1-phosphate comportant des cycloalcanes et heterocycles substitues par des groupes amino et phenyle
US20060199853A1 (en) 2005-02-18 2006-09-07 Charles Mioskowski Analogs of 4-hydroxyisoleucine and uses thereof
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2006100633A1 (fr) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd Nouveaux derives de thiophene en tant qu'agonistes du recepteur de sphingosine-l-phosphate-1
WO2006115188A1 (fr) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Compose heterocyclique
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
KR20080086546A (ko) 2006-01-27 2008-09-25 유니버시티 오브 버지니아 페이턴트 파운데이션 신경병증성 통증의 치료 방법
WO2007088450A2 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagoniste du récepteur h-3
WO2007109330A2 (fr) 2006-03-21 2007-09-27 Epix Delaware, Inc. Composés modulant le récepteur de la sip
WO2007111864A2 (fr) 2006-03-23 2007-10-04 Merck & Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
EP2003132B1 (fr) 2006-04-03 2014-03-05 Astellas Pharma Inc. Dérivés d'oxadiazole en tant qu'agonistes du S1P1
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
CL2007002594A1 (es) 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
BRPI0720478A2 (pt) * 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
CA2675221C (fr) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
ES2431354T3 (es) 2008-04-01 2013-11-26 Theravance, Inc. Derivados de 2-aminotetralina como antagonistas del receptor de opioide mu
CA2739901A1 (fr) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd Modulateurs des recepteurs s1p
US8741923B2 (en) 2008-12-18 2014-06-03 Merck Serono Sa Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
EP2210890A1 (fr) 2009-01-19 2010-07-28 Almirall, S.A. Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
EP2389377B1 (fr) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
WO2010085581A1 (fr) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
CN102316862A (zh) 2009-02-10 2012-01-11 雅培制药有限公司 制备s1p受体激动剂或拮抗剂的方法
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
AU2010319879A1 (en) 2009-10-29 2012-06-14 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
JP5735634B2 (ja) 2010-04-23 2015-06-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
WO2012040532A1 (fr) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Composés oxadiazoles substitués et leur utilisation en tant qu'agonistes du s1p1
JP2013544811A (ja) 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物
EP2685971A4 (fr) 2011-03-18 2014-01-22 Univ Virginia Patent Found Compositions et méthodes utilisées pour l'ingénierie tissulaire et des thérapies fondées sur des cellules
JP5090580B1 (ja) 2011-04-26 2012-12-05 パナソニック株式会社 暖房システム及び暖房システム制御方法
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
BR112015001613B1 (pt) 2012-07-27 2021-02-23 Biogen Ma Inc compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica

Also Published As

Publication number Publication date
SMT201700115B (it) 2017-03-08
ES2613262T3 (es) 2017-05-23
TN2015000356A1 (en) 2017-01-03
US9487481B2 (en) 2016-11-08
AR094851A1 (es) 2015-09-02
PL2958888T3 (pl) 2017-07-31
US9115054B2 (en) 2015-08-25
PH12015501793A1 (en) 2015-11-09
CN105026362B (zh) 2017-07-14
AU2014218883B2 (en) 2017-05-11
EP2958888B1 (fr) 2016-11-23
IL240613B (en) 2018-06-28
BR112015019919A2 (pt) 2017-07-18
MY173990A (en) 2020-03-03
HRP20170247T1 (hr) 2017-04-07
MA38425B1 (fr) 2019-03-29
US20150315128A1 (en) 2015-11-05
IL240613A0 (en) 2015-10-29
ZA201506965B (en) 2017-08-30
EA025294B1 (ru) 2016-12-30
TW201444786A (zh) 2014-12-01
LT2958888T (lt) 2017-02-10
RS55703B1 (sr) 2017-07-31
TWI613182B (zh) 2018-02-01
UY35338A (es) 2014-08-29
CL2015002358A1 (es) 2016-02-26
SG11201506408TA (en) 2015-09-29
SI2958888T1 (sl) 2017-01-31
CA2902168C (fr) 2019-01-08
PH12015501793B1 (en) 2015-11-09
US20160251309A1 (en) 2016-09-01
EP2958888A2 (fr) 2015-12-30
KR102242265B1 (ko) 2021-04-19
JP6277210B2 (ja) 2018-02-07
US20140235591A1 (en) 2014-08-21
JP2016513124A (ja) 2016-05-12
WO2014130752A2 (fr) 2014-08-28
CY1118641T1 (el) 2017-07-12
WO2014130752A3 (fr) 2014-10-23
CA2902168A1 (fr) 2014-08-28
SMT201700115T1 (it) 2017-03-08
PT2958888T (pt) 2017-02-03
CN105026362A (zh) 2015-11-04
KR20150119352A (ko) 2015-10-23
PE20151746A1 (es) 2015-12-02
DK2958888T3 (en) 2017-03-06
US9359286B2 (en) 2016-06-07
HUE031626T2 (en) 2017-07-28
EA201591409A1 (ru) 2015-12-30
AU2014218883A1 (en) 2015-10-15
HK1218111A1 (en) 2017-02-03
MX2015010347A (es) 2015-11-16

Similar Documents

Publication Publication Date Title
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA35036B1 (fr) Composés bis(fluoroalkyl)-1,4-benzodiazépinone
MA40290A1 (fr) Agents immunorégulateurs
MA41988B1 (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MA37929A1 (fr) Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA39186A1 (fr) Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2